William Lang

2.4k total citations
50 papers, 1.9k citations indexed

About

William Lang is a scholar working on Virology, Infectious Diseases and General Health Professions. According to data from OpenAlex, William Lang has authored 50 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Virology, 14 papers in Infectious Diseases and 11 papers in General Health Professions. Recurrent topics in William Lang's work include HIV Research and Treatment (15 papers), Pharmaceutical Practices and Patient Outcomes (10 papers) and HIV/AIDS drug development and treatment (10 papers). William Lang is often cited by papers focused on HIV Research and Treatment (15 papers), Pharmaceutical Practices and Patient Outcomes (10 papers) and HIV/AIDS drug development and treatment (10 papers). William Lang collaborates with scholars based in United States, United Kingdom and France. William Lang's co-authors include Warren Winkelstein, Robert E. Anderson, Jay A. Levy, Haynes W. Sheppard, Rachel A. Royce, James Wiley, Nancy Padian, Eric Vittinghoff, Nicholas P. Jewell and H. A. Perkins and has published in prestigious journals such as JAMA, Neurology and American Journal of Public Health.

In The Last Decade

William Lang

49 papers receiving 1.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
William Lang 899 712 629 404 217 50 1.9k
Jacqueline Astemborski 668 0.7× 371 0.5× 816 1.3× 305 0.8× 121 0.6× 30 1.7k
K. G. Castro 2.1k 2.3× 1.3k 1.9× 1.6k 2.5× 349 0.9× 195 0.9× 5 3.8k
Nagalingeswaran Kumarasamy 1.3k 1.5× 720 1.0× 617 1.0× 117 0.3× 181 0.8× 97 1.8k
Antonio Ocampo 1.0k 1.2× 587 0.8× 704 1.1× 115 0.3× 78 0.4× 86 1.8k
Elizabeth Cooney 456 0.5× 456 0.6× 970 1.5× 760 1.9× 355 1.6× 61 2.8k
Andrew Wiznia 2.2k 2.5× 1.5k 2.1× 693 1.1× 265 0.7× 549 2.5× 130 3.3k
Suniti Solomon 2.1k 2.3× 750 1.1× 1.8k 2.8× 277 0.7× 578 2.7× 100 3.1k
Stanley Read 1.5k 1.6× 749 1.1× 1.1k 1.8× 292 0.7× 469 2.2× 142 3.4k
Víctoria Hernando 1.1k 1.2× 379 0.5× 804 1.3× 106 0.3× 342 1.6× 55 1.5k
Rohan Hazra 2.7k 3.0× 1.1k 1.6× 1.1k 1.7× 405 1.0× 493 2.3× 134 4.1k

Countries citing papers authored by William Lang

Since Specialization
Citations

This map shows the geographic impact of William Lang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Lang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Lang more than expected).

Fields of papers citing papers by William Lang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Lang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Lang. The network helps show where William Lang may publish in the future.

Co-authorship network of co-authors of William Lang

This figure shows the co-authorship network connecting the top 25 collaborators of William Lang. A scholar is included among the top collaborators of William Lang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Lang. William Lang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bratberg, Jeffrey, et al.. (2017). The Report of the 2016-2017 Advocacy Standing Committee. American Journal of Pharmaceutical Education. 81(8). S10–S10. 4 indexed citations
2.
3.
Kropp, Wolfgang, et al.. (2014). Quieter cities of the future. Chalmers Publication Library (Chalmers University of Technology). 3 indexed citations
4.
Albano, Christian B., et al.. (2014). Report of the 2013-2014 AACP Standing Committee on Advocacy: Improving Advocacy through the Use of Implementation Science Concepts and Frameworks. American Journal of Pharmaceutical Education. 78(10). S20–S20. 3 indexed citations
5.
Smith, Marie, et al.. (2013). Report of the 2012-2013 Standing Committee on Advocacy: Advocacy Tools and Resources: A Framework for Increasing Member Engagement. American Journal of Pharmaceutical Education. 77(10). S17–S17. 3 indexed citations
6.
Allen, David D., et al.. (2012). Report of the 2011-2012 Standing Committee on Advocacy: The Relevance of Excellent Research: Strategies for Impacting Public Policy. American Journal of Pharmaceutical Education. 76(6). S6–S6. 2 indexed citations
7.
Maeshiro, Rika, Clyde H. Evans, Joan Stanley, et al.. (2011). Using the Clinical Prevention and Population Health Curriculum Framework to Encourage Curricular Change. American Journal of Preventive Medicine. 40(2). 232–244. 14 indexed citations
8.
Lang, William. (2011). The Role of Academic Pharmacy to Influence Safety Through Science and Education. American Journal of Pharmaceutical Education. 75(4). 78–78. 5 indexed citations
9.
Kehrer, James P., et al.. (2009). Report of the 2008–2009 Standing Committee on Advocacy. American Journal of Pharmaceutical Education. 73(8). S08–S08. 1 indexed citations
10.
Lang, William. (2009). Focusing the Academy's Strengths to Reorganize Healthcare. American Journal of Pharmaceutical Education. 73(6). 113–113. 1 indexed citations
11.
Lang, William. (2008). Musings on America's Birthday. American Journal of Pharmaceutical Education. 72(4). 82–82. 1 indexed citations
12.
Haubrich, Richard, William Lang, Judith Millard, et al.. (2001). A Phase II Trial of Dual Protease Inhibitor Therapy: Amprenavir in Combination With Indinavir, Nelfinavir, or Saquinavir. JAIDS Journal of Acquired Immune Deficiency Syndromes. 26(5). 458–461. 15 indexed citations
13.
Haubrich, Richard, Melanie Thompson, Robert T. Schooley, et al.. (1999). A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. AIDS. 13(17). 2411–2420. 23 indexed citations
14.
Lifson, Alan R., Joan F. Hilton, Janice Westenhouse, et al.. (1994). Time from HIV seroconversion to oral candidiasis or hairy leukoplakia among homosexual and bisexual men enrolled in three prospective cohorts. AIDS. 8(1). 73–80. 83 indexed citations
15.
Lang, William, et al.. (1993). Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.. PubMed. 6(2). 191–5. 8 indexed citations
16.
Katz, Mitchell H., Deborah Greenspan, Janice Westenhouse, et al.. (1992). Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS. 6(1). 95–100. 112 indexed citations
17.
Feigal, David W., Mitchell H. Katz, Deborah Greenspan, et al.. (1991). The prevalence of oral lesions in HIV-infected homosexual and bisexual men. AIDS. 5(5). 519–526. 199 indexed citations
18.
Jacobson, Mark Z., Robert E. Fusaro, M. Galmarini, & William Lang. (1991). Decreased Serum Dehydroepiandrosterone Is Associated with an Increased Progression of Human Immunodeficiency Virus Infection in Men with CD4 Cell Counts of 200-499. The Journal of Infectious Diseases. 164(5). 864–868. 63 indexed citations
19.
Miller, Robert G., et al.. (1988). The spectrum of peripheral neuropathy associated with ARC and AIDS. Muscle & Nerve. 11(8). 857–863. 61 indexed citations
20.
Kiprov, D, et al.. (1988). Antibody‐mediated peripheral neuropathies associated with ARC and AIDS: Successful treatment with plasmapheresis. Journal of Clinical Apheresis. 4(1). 3–7. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqueline Astemborski Breakdown of academic impact, for papers by K. G. Castro Breakdown of academic impact, for papers by Nagalingeswaran Kumarasamy Breakdown of academic impact, for papers by Antonio Ocampo Breakdown of academic impact, for papers by Elizabeth Cooney Breakdown of academic impact, for papers by Andrew Wiznia Breakdown of academic impact, for papers by Suniti Solomon Breakdown of academic impact, for papers by Stanley Read Breakdown of academic impact, for papers by Víctoria Hernando Breakdown of academic impact, for papers by Rohan Hazra
Rankless by CCL
2026